13F filer · CIK 1642343
Bellevue Asset Management AG
ZURICH, V8 · filing since Q1 2015 · last filing Aug 14, 2026
Reported value
$656.3M
+$43.2M vs prior
Positions
127
New / sold out
9 / 15
Added / reduced
39 / 25
Turnover
12.2%
buys $77.8M · sells $77.4M
Top-10 weight
31.0%
Biggest buys vs Q3 2015
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Ionis Pharmaceuticals Inc. | +138,000 | – | +$8.5M |
| Added | Cardinal Health, Inc. | +91,480 | +114.3% | +$8.2M |
| Added | Centene Corporation | +85,630 | +428.2% | +$5.6M |
| Added | Mylan Inc. | +90,300 | +40.1% | +$4.9M |
| New | EAGLE PHARMACEUTICALS INC | +55,000 | – | +$4.9M |
| New | Lannett Inc. | +107,480 | – | +$4.3M |
| Added | CVSCVS Health Corporation | +41,200 | +74.9% | +$4.0M |
| Added | Biogen Inc. | +12,260 | +17.1% | +$3.8M |
| New | Radius Health Inc. | +40,000 | – | +$2.5M |
| Added | Baxter International Inc. | +60,000 | +120.0% | +$2.3M |
38 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q3 2015
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Allergan PLC | -50,150 | -100.0% | $-13.6M |
| Sold out | Dr. Reddy's Laboratories Limited | -130,000 | -100.0% | $-8.3M |
| Reduced | Kite Pharma, Inc. | -105,500 | -88.3% | $-6.5M |
| Sold out | Isis Pharmaceuticals, Inc. | -132,000 | -100.0% | $-5.3M |
| Reduced | Abbott Laboratories | -81,500 | -17.6% | $-3.7M |
| Reduced | Tenet Healthcare Corporation | -116,510 | -92.1% | $-3.5M |
| Sold out | Akorn, Inc. | -112,470 | -100.0% | $-3.2M |
| Sold out | Zafgen Inc. | -100,000 | -100.0% | $-3.2M |
| Reduced | Express Scripts Holding Company | -36,000 | -22.5% | $-3.1M |
| Sold out | DENTSPLY International Inc. | -58,400 | -100.0% | $-3.0M |
30 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q4 2015
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Celgene CorporationCOM | 217,410 | $26.0M | 3.97% |
| 2 | Biogen Inc.COM | 84,030 | $25.7M | 3.92% |
| 3 | Gilead Sciences, Inc.COM | 240,120 | $24.3M | 3.70% |
| 4 | Amgen Inc.COM | 123,000 | $20.0M | 3.04% |
| 5 | Regeneron Pharmaceuticals, Inc.COM | 36,400 | $19.8M | 3.01% |
| 6 | Medtronic, Inc.COM | 256,500 | $19.7M | 3.01% |
| 7 | Illumina, Inc.COM | 91,425 | $17.5M | 2.67% |
| 8 | Abbott LaboratoriesCOM | 381,500 | $17.1M | 2.61% |
| 9 | Mylan Inc.COM | 315,300 | $17.0M | 2.60% |
| 10 | Becton, Dickinson and CompanyCOM | 105,075 | $16.2M | 2.47% |
117 more rows. Subscribe for $29/month to see every row, download the data and use the API.